Brief: Cereno Scientific Lead Candidate CS1 Trial Meets Primary Endpoint

Cereno Scientific AB

25/02/2025 07:08

Feb 25 (Reuters) - Cereno Scientific AB  CRNOSb.ST :
    * LEAD CANDIDATE CS1'S REVERSE VASCULAR REMODELING PROFILE
IS
ACCOMPANIED BY IMPROVEMENT OF RIGHT-VENTRICULAR FUNCTION IN
ADDITIONAL DATA FROM PHASE IIA TRIAL
    * TRIAL SUCCESSFULLY MET ITS PRIMARY ENDPOINT OF SAFETY AND
TOLERABILITY, WITH NO DRUG RELATED SERIOUS ADVERSE EVENTS

Source text:  ID:nWkr3vzTd3 
Further company coverage:  CRNOSb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))